BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Siddiqui MT, Amin H, Garg R, Chadalavada P, Al-Yaman W, Lopez R, Singh A. Medications in type-2 diabetics and their association with liver fibrosis. World J Gastroenterol 2020; 26(23): 3249-3259 [PMID: 32684739 DOI: 10.3748/wjg.v26.i23.3249]
URL: https://www.wjgnet.com/1007-9327/full/v26/i23/3249.htm
Number Citing Articles
1
Tingting Zhou, Ligang Cao, Yimei Du, Lin Qin, Yanliu Lu, Qianru Zhang, Yuqi He, Daopeng Tan. Gypenosides ameliorate high-fat diet-induced nonalcoholic fatty liver disease in mice by regulating lipid metabolismPeerJ 2023; 11: e15225 doi: 10.7717/peerj.15225
2
Timo Itzel, Thomas Falconer, Ana Roig, Jimmy Daza, Jimyung Park, Jae Youn Cheong, Rae Woong Park, Isabella Wiest, Matthias P Ebert, George Hripcsak, Andreas Teufel. Efficacy of Co-Medications in Patients with Alcoholic Liver DiseaseDigestive Diseases 2023; 41(5): 780 doi: 10.1159/000529914
3
Carollyne Rodovalho Guerra Carneiro, Arthur Balestra Silveira Ayres, Martinho Antonio Gestic, Murillo Pimentel Utrini, Felipe David Mendonça Chaim, Francisco Callejas-Neto, Elinton Adami Chaim, Everton Cazzo. Association of Histopathological and Biochemical Aspects of NAFLD With the Severity of Liver Fibrosis in Individuals With Obesity: Cross-sectional StudyObesity Surgery 2024;  doi: 10.1007/s11695-024-07180-x
4
Clelia Asero, Annalisa Giandalia, Irene Cacciola, Carmela Morace, Giuseppe Lorello, Amalia Rita Caspanello, Angela Alibrandi, Giovanni Squadrito, Giuseppina T. Russo. High Prevalence of Severe Hepatic Fibrosis in Type 2 Diabetic Outpatients Screened for Non-Alcoholic Fatty Liver DiseaseJournal of Clinical Medicine 2023; 12(8): 2858 doi: 10.3390/jcm12082858
5
Anqi Zhang, Fangyi Qian, Yangyang Li, Bowen Li, Furong Yang, Chengmu Hu, Wuyi Sun, Yan Huang. Research progress of metformin in the treatment of liver fibrosisInternational Immunopharmacology 2023; 116: 109738 doi: 10.1016/j.intimp.2023.109738
6
Chia-Yen Dai, Tzu-Jung Fang, Wei-Wen Hung, Hui-Ju Tsai, Yi-Chun Tsai. The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes MellitusBiomedicines 2022; 10(7): 1487 doi: 10.3390/biomedicines10071487
7
Jose Arriola-Montenegro, Renato Beas, Renato Cerna-Viacava, Andres Chaponan-Lavalle, Karla Hernandez Randich, Diego Chambergo-Michilot, Herson Flores Sanga, Pornthira Mutirangura. Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver diseaseWorld Journal of Cardiology 2023; 15(7): 328-341 doi: 10.4330/wjc.v15.i7.328
8
Xiu-Ping Bai, Ting-Ting Li, Lai-Li Guo, Jing Wang, Feng Dong. The Influence of Hyperglycemia on Liver Triglyceride Deposition in Partially Pancreatectomized RatsHormone and Metabolic Research 2024; 56(02): 159 doi: 10.1055/a-2198-1132
9
Federica Perazza, Laura Leoni, Santo Colosimo, Alessandra Musio, Giulia Bocedi, Michela D’Avino, Giulio Agnelli, Alba Nicastri, Chiara Rossetti, Federica Sacilotto, Giulio Marchesini, Maria Letizia Petroni, Federico Ravaioli. Metformin and the Liver: Unlocking the Full Therapeutic PotentialMetabolites 2024; 14(4): 186 doi: 10.3390/metabo14040186
10
Apostolis PAPAEFTHYMIOU, Michael DOULBERIS, Kyriaki KARAFYLLIDOU, Eleftherios CHATZIMICHAEL, Georgia DERETZI, Aristomenis K. EXADAKTYLOS, Fotios SAMPSONAS, Athanasios GELASAKIS, Spyros I. PAPAMICHOS, Georgios KOTRONIS, Dimitra GIALAMPRINOU, Elisabeth VARDAKA, Stergios A. POLYZOS, Jannis KOUNTOURAS. Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver diseaseMinerva Endocrinology 2023; 48(3) doi: 10.23736/S2724-6507.21.03564-8
11
Michele Finotti, Maurizio Romano, Pasquale Auricchio, Michele Scopelliti, Marco Brizzolari, Ugo Grossi, Marco Piccino, Stefano Benvenuti, Giovanni Morana, Umberto Cillo, Giacomo Zanus. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical AlternativesJournal of Personalized Medicine 2021; 11(6): 499 doi: 10.3390/jpm11060499
12
Seong-Woo Choi, Sun-Seog Kweon, Young-Hoon Lee, So-Yeon Ryu, Hae-Sung Nam, Min-Ho Shin, Taeyun Kim. Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: The Dong-gu studyPLOS ONE 2022; 17(12): e0277729 doi: 10.1371/journal.pone.0277729
13
L. B. Lasebnik, L. N. Chikhireva, O. A. Chikhirev, E. D. Li. Choice of antihyprtensive therapy at varios stages of metabolically associated lever diseaseExperimental and Clinical Gastroenterology 2024; (11): 52 doi: 10.31146/1682-8658-ecg-219-11-52-61